VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
ZURICH, SWITZERLAND – July 10, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim Chief Financial Officer. He succeeds Torsten …